The objective of this study was to determine the potential of osteopontin (OPN) and OPN + CA125 (cancer antigen 125) combination in differential diagnosis of the ovarian cancers and non-malignant ovarian disease. Serum and plasma samples were obtained preoperatively from 79 women undergoing surgery for pelvic mass; 48 of them had ovarian carcinoma, and 31 had benign cyst. The samples were analyzed for the levels of OPN and CA 125 (using ELISA and CMIA methods) and then compared with the final pathologic results. The median plasma level of OPN in patients with benign and malignant cysts was 356.33 ng/ml and 865.15 ng/ml, respectively (p lt 0.001). Receiver operating characteristic (ROC) analysis for plasma OPN revealed the area under the curve (AUC) of 0.838. At the predefined specificity of 90%, OPN showed sensitivity of 62.5%, whereas the combination of OPN + CA125 reached 74.9% at the same specificity.
Keywords:
Ovarian cancer / Osteopontin / CA125 / Tumor markers
Source:
European Journal of Gynaecological Oncology, 2013, 34, 1, 83-85
TY - JOUR
AU - Milivojevic, M.
AU - Bošković, V.
AU - Atanackovic, J.
AU - Milicevic, S.
AU - Ražić, Slavica
AU - Kastratović-Kotlica, Biljana
PY - 2013
UR - http://farfar.pharmacy.bg.ac.rs/handle/123456789/1950
AB - The objective of this study was to determine the potential of osteopontin (OPN) and OPN + CA125 (cancer antigen 125) combination in differential diagnosis of the ovarian cancers and non-malignant ovarian disease. Serum and plasma samples were obtained preoperatively from 79 women undergoing surgery for pelvic mass; 48 of them had ovarian carcinoma, and 31 had benign cyst. The samples were analyzed for the levels of OPN and CA 125 (using ELISA and CMIA methods) and then compared with the final pathologic results. The median plasma level of OPN in patients with benign and malignant cysts was 356.33 ng/ml and 865.15 ng/ml, respectively (p lt 0.001). Receiver operating characteristic (ROC) analysis for plasma OPN revealed the area under the curve (AUC) of 0.838. At the predefined specificity of 90%, OPN showed sensitivity of 62.5%, whereas the combination of OPN + CA125 reached 74.9% at the same specificity.
PB - I R O G Canada, Inc, Montreal
T2 - European Journal of Gynaecological Oncology
T1 - Evaluation of osteopontin and CA125 in detection of epithelial ovarian carcinoma
VL - 34
IS - 1
SP - 83
EP - 85
ER -
@article{
author = "Milivojevic, M. and Bošković, V. and Atanackovic, J. and Milicevic, S. and Ražić, Slavica and Kastratović-Kotlica, Biljana",
year = "2013",
url = "http://farfar.pharmacy.bg.ac.rs/handle/123456789/1950",
abstract = "The objective of this study was to determine the potential of osteopontin (OPN) and OPN + CA125 (cancer antigen 125) combination in differential diagnosis of the ovarian cancers and non-malignant ovarian disease. Serum and plasma samples were obtained preoperatively from 79 women undergoing surgery for pelvic mass; 48 of them had ovarian carcinoma, and 31 had benign cyst. The samples were analyzed for the levels of OPN and CA 125 (using ELISA and CMIA methods) and then compared with the final pathologic results. The median plasma level of OPN in patients with benign and malignant cysts was 356.33 ng/ml and 865.15 ng/ml, respectively (p lt 0.001). Receiver operating characteristic (ROC) analysis for plasma OPN revealed the area under the curve (AUC) of 0.838. At the predefined specificity of 90%, OPN showed sensitivity of 62.5%, whereas the combination of OPN + CA125 reached 74.9% at the same specificity.",
publisher = "I R O G Canada, Inc, Montreal",
journal = "European Journal of Gynaecological Oncology",
title = "Evaluation of osteopontin and CA125 in detection of epithelial ovarian carcinoma",
volume = "34",
number = "1",
pages = "83-85"
}
Milivojevic M, Bošković V, Atanackovic J, Milicevic S, Ražić S, Kastratović-Kotlica B. Evaluation of osteopontin and CA125 in detection of epithelial ovarian carcinoma. European Journal of Gynaecological Oncology. 2013;34(1):83-85
Milivojevic, M., Bošković, V., Atanackovic, J., Milicevic, S., Ražić, S.,& Kastratović-Kotlica, B. (2013). Evaluation of osteopontin and CA125 in detection of epithelial ovarian carcinoma.
European Journal of Gynaecological OncologyI R O G Canada, Inc, Montreal., 34(1), 83-85.
Milivojevic M., Bošković V., Atanackovic J., Milicevic S., Ražić Slavica, Kastratović-Kotlica Biljana, "Evaluation of osteopontin and CA125 in detection of epithelial ovarian carcinoma" 34, no. 1 (2013):83-85
